Grant  Pickering net worth and biography

Grant Pickering Biography and Net Worth

CEO of Vaxcyte
Grant has nearly 30 years of experience in the pharmaceutical and biotech arena having responsibility for multiple vaccines and immunotherapeutic drug approvals and the formation and financing of multiple successful platform companies. Prior to starting Vaxcyte, Mr. Pickering was the CEO of Mymetics Corporation, a public European-based vaccine company developing a prophylactic RSV vaccine, based on a virosomal platform technology. Prior to that, he was an executive-in-residence at Kleiner, Perkins, Caufield & Byers, while serving as the CEO at Juvaris BioTherapeutics, whose immunotherapeutic and vaccine adjuvant platform yielded multiple animal health products launched by its alliance partner Bayer HealthCare, including Zelnate® and Victrio®. Prior to Juvaris, Mr. Pickering spent many years at Dendreon Corporation where he played a prominent role in the company’s IPO and led clinical development, operations and business development culminating in the launch of the therapeutic prostate cancer vaccine, Provenge®. He also led marketing and business development for the pain management platform company, Algos Pharmaceutical Corporation, which was acquired by Endo Pharmaceuticals. Mr. Pickering began his career at Glaxo and Johnson & Johnson in sales, marketing, and clinical research roles culminating in the launches of Flonase® and Floxin®. Mr. Pickering earned his BS degree in marketing from The Pennsylvania State University and his MBA from Georgetown University with high honors. Outside of Vaxcyte, Grant enjoys spending time with his wife and kids, living vicariously through their soccer triumphs, and gives back through mentoring and supporting education both domestically and in developing countries. Grant’s loyalty to his hometown of Kansas City was finally doubly rewarded as both the Royals and the Chiefs were crowned world champions since Vaxcyte got rolling.

What is Grant Pickering's net worth?

The estimated net worth of Grant Pickering is at least $32.64 million as of March 25th, 2024. Mr. Pickering owns 477,847 shares of Vaxcyte stock worth more than $32,641,729 as of March 28th. This net worth estimate does not reflect any other assets that Mr. Pickering may own. Additionally, Mr. Pickering receives a salary of $1,100,000.00 as CEO at Vaxcyte. Learn More about Grant Pickering's net worth.

How old is Grant Pickering?

Mr. Pickering is currently 56 years old. There are 6 older executives and no younger executives at Vaxcyte. Learn More on Grant Pickering's age.

What is Grant Pickering's salary?

As the CEO of Vaxcyte, Inc., Mr. Pickering earns $1,100,000.00 per year. Learn More on Grant Pickering's salary.

How do I contact Grant Pickering?

The corporate mailing address for Mr. Pickering and other Vaxcyte executives is 353 HATCH DRIVE, FOSTER CITY CA, 94404. Vaxcyte can also be reached via phone at 650-837-0111 and via email at [email protected]. Learn More on Grant Pickering's contact information.

Has Grant Pickering been buying or selling shares of Vaxcyte?

In the last ninety days, Grant Pickering has sold $4,496,934.00 in Vaxcyte stock. Most recently, Grant Pickering sold 15,000 shares of the business's stock in a transaction on Monday, March 25th. The shares were sold at an average price of $66.93, for a transaction totalling $1,003,950.00. Following the completion of the sale, the chief executive officer now directly owns 477,847 shares of the company's stock, valued at $31,982,299.71. Learn More on Grant Pickering's trading history.

Who are Vaxcyte's active insiders?

Vaxcyte's insider roster includes Mikhail Eydelman (SVP), Jeff Fairman (VP), Andrew Guggenhime (CFO), Heath Lukatch (Director), Grant Pickering (CEO), Paul Sauer (SVP), James Wassil (COO), Jim Wassil (COO), and Jane Wright-Mitchell (General Counsel). Learn More on Vaxcyte's active insiders.

Are insiders buying or selling shares of Vaxcyte?

In the last year, insiders at the sold shares 31 times. They sold a total of 258,096 shares worth more than $15,413,377.62. The most recent insider tranaction occured on March, 25th when CEO Grant Pickering sold 15,000 shares worth more than $1,003,950.00. Insiders at Vaxcyte own 3.6% of the company. Learn More about insider trades at Vaxcyte.

Information on this page was last updated on 3/25/2024.

Grant Pickering Insider Trading History at Vaxcyte

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/25/2024Sell15,000$66.93$1,003,950.00477,847View SEC Filing Icon  
3/1/2024Sell2,616$73.70$192,799.20148,670View SEC Filing Icon  
2/1/2024Sell2,616$73.91$193,348.56149,978View SEC Filing Icon  
1/29/2024Sell30,000$66.03$1,980,900.00375,814View SEC Filing Icon  
1/23/2024Sell15,000$63.92$958,800.00375,814View SEC Filing Icon  
1/2/2024Sell2,616$63.89$167,136.24151,286View SEC Filing Icon  
12/26/2023Sell15,000$61.70$925,500.00375,814View SEC Filing Icon  
11/24/2023Sell15,000$49.09$736,350.00370,914View SEC Filing Icon  
11/1/2023Sell2,618$47.29$123,805.22153,903View SEC Filing Icon  
10/23/2023Sell15,000$47.07$706,050.00385,914View SEC Filing Icon  
10/2/2023Sell2,618$50.42$131,999.56155,212View SEC Filing Icon  
9/25/2023Sell15,000$52.45$786,750.00400,914View SEC Filing Icon  
9/26/2022Sell10,000$24.71$247,100.00157,830View SEC Filing Icon  
9/15/2022Sell11,000$27.95$307,450.00652,546View SEC Filing Icon  
8/26/2022Sell10,000$27.44$274,400.00162,830View SEC Filing Icon  
7/26/2022Sell10,000$23.27$232,700.00167,830View SEC Filing Icon  
7/15/2022Sell11,000$24.47$269,170.00683,456View SEC Filing Icon  
6/28/2022Sell10,000$21.00$210,000.00345,660View SEC Filing Icon  
6/23/2022Sell3,541$21.01$74,396.41695,203View SEC Filing Icon  
6/21/2022Sell5,451$21.05$114,743.55700,005View SEC Filing Icon  
5/16/2022Sell11,000$23.91$263,010.00703,894View SEC Filing Icon  
4/18/2022Sell11,000$23.98$263,780.00703,894View SEC Filing Icon  
3/21/2022Sell14,288$24.94$356,342.72View SEC Filing Icon  
11/19/2021Sell15,000$23.45$351,750.00View SEC Filing Icon  
10/20/2021Sell15,000$22.58$338,700.00View SEC Filing Icon  
9/21/2021Sell10,807$25.22$272,552.54View SEC Filing Icon  
8/23/2021Sell13,669$22.73$310,696.37593,923View SEC Filing Icon  
7/20/2021Sell15,000$22.85$342,750.00595,254View SEC Filing Icon  
6/24/2021Sell13,863$23.09$320,096.67594,117View SEC Filing Icon  
6/21/2021Sell1,063$22.05$23,439.15581,317View SEC Filing Icon  
6/4/2021Sell8,093$22.14$179,179.02587,259View SEC Filing Icon  
5/27/2021Sell12,246$22.10$270,636.60View SEC Filing Icon  
3/19/2021Sell15,000$25.77$386,550.00593,691View SEC Filing Icon  
1/19/2021Sell15,000$25.10$376,500.00593,691View SEC Filing Icon  
12/21/2020Sell15,000$28.88$433,200.00View SEC Filing Icon  
See Full Table

Grant Pickering Buying and Selling Activity at Vaxcyte

This chart shows Grant Pickering's buying and selling at Vaxcyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vaxcyte Company Overview

Vaxcyte logo
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $68.31
Low: $67.55
High: $69.69

50 Day Range

MA: $71.21
Low: $60.57
High: $81.05

2 Week Range

Now: $68.31
Low: $34.11
High: $82.04

Volume

731,552 shs

Average Volume

877,978 shs

Market Capitalization

$7.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.91